FDA’s plausible mechanism framework aims to accelerate and expand drug development for patients with rare genetically driven diseases, but ambition alone won’t deliver. The intellectual and institutional scaffolding needed to move from an artisanal to an industrial approach to individualized medicines is missing.
With its current leadership, staffing and resources, FDA cannot create that scaffolding.
